nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

01.07.2007 | Review

Immunotherapy of myeloid leukaemia

verfasst von: Barbara-Ann Guinn, Azim Mohamedali, N. Shaun B. Thomas, Ken I. Mills

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Abstract

The treatment of myeloid leukaemia has progressed in recent years with the advent of donor leukocyte infusions (DLI), haemopoietic stem cell transplants (HSCTs) and targeted therapies. However, relapse has a high associated morbidity rate and a method for removing diseased cells in first remission, when a minimal residual disease state is achieved and tumour load is low, has the potential to extend remission times and prevent relapse especially when used in combination with conventional treatments. Acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) are heterogeneous diseases which lack one common molecular target while chronic myeloid leukaemia (CML) patients have experienced prolonged remissions through the use of targeted therapies which remove BCR-ABL⁺ cells effectively in early chronic phase. However, escape mutants have arisen and this therapy has little effectivity in the late chronic phase. Here we review the immune therapies which are close to or in clinical trials for the myeloid leukaemias and describe their potential advantages and disadvantages.

Adams SP, Sahota SS, Mijovic A, Czepulkowski B, Padua RA, Mufti GJ, Guinn BA (2002) Frequent expression of HAGE in presentation chronic myeloid leukaemias. Leukemia 16:2238–2242PubMedCrossRef

Andersen MH, Svane IM, Kvistborg P, Nielsen OJ, Balslev E, Reker S, Becker JC, Straten PT (2005) Immunogenicity of Bcl-2 in patients with cancer. Blood 105:728–734PubMedCrossRef

Bae J, Martinson JA, Klingemann HG (2004) Heteroclitic CD33 peptide with enhanced anti-acute myeloid leukemic immunogenicity. Clin Cancer Res 10:7043–7052PubMedCrossRef

Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, Amabile M, Forconi F, Gozzetti A, Raspadori D, Amadori S, Lauria F (2005) Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365:657–662PubMed

Buggins AG, Milojkovic D, Arno MJ, Lea NC, Mufti GJ, Thomas NS, Hirst WJ (2001) Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways. J Immunol 167:6021–6030PubMed

Bullinger L, Valk PJ (2005) Gene expression profiling in acute myeloid leukemia. J Clin Oncol 23:6296–6305PubMedCrossRef

Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, Scheinberg DA (2004) A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103:1037–1042PubMedCrossRef

Chambost H, Brasseur F, Coulie P, de Plaen E, Stoppa AM, Baume D, Mannoni P, Boon T, Maraninchi D, Olive D (1993) A tumour-associated antigen expression in human haematological malignancies. Br J Haematol 84:524–526PubMed

Chambost H, van Baren N, Brasseur F, Olive D (2001) MAGE-A genes are not expressed in human leukemias. Leukemia 15:1769–1771PubMed

10.

Chan L, Hardwick N, Darling D, Galea-Lauri J, Gaken J, Devereux S, Kemeny M, Mufti G, Farzaneh F (2005) IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. Mol Ther 11:120–131PubMedCrossRef

11.

Chan L, Hardwick NR, Guinn BA, Darling D, Gaken J, Galea-Lauri J, Ho AY, Mufti GJ, Farzaneh F (2006) An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia. Cancer Immunol Immunother 55:1017–1024PubMedCrossRef

12.

Chen DS, Soen Y, Stuge TB, Lee PP, Weber JS, Brown PO, Davis MM (2005) Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med 2:e265PubMedCrossRef

13.

Chen G, Zhang W, Cao X, Li F, Liu X, Yao L (2005) Serological identification of immunogenic antigens in acute monocytic leukemia. Leuk Res 29:503–509PubMedCrossRef

14.

Cheuk AT, Chan L, Czepulkowski B, Berger SA, Yagita H, Okumura K, Farzaneh F, Mufti GJ, Guinn BA (2006) Development of a whole cell vaccine for acute myeloid leukaemia. Cancer Immunol Immunother 55:68–75PubMedCrossRef

15.

Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR, Rojas J, Bourdon A, Bonner PL, Wang L, Christmas SE, Travers PJ, Creaser CS, Rees RC, Madrigal JA (2001) Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 98:2887–2893PubMedCrossRef

16.

Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E, McArthur G, MacGregor D, Sturrock S, Tai TY, Green S, Cuthbertson A, Maher D, Miloradovic L, Mitchell SV, Ritter G, Jungbluth AA, Chen YT, Gnjatic S, Hoffman EW, Old LJ, Cebon JS (2004) Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 101:10697–10702PubMedCrossRef

17.

Gaiger A, Reese V, Disis ML, Cheever MA (2000) Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 96:1480–1489PubMed

18.

Galea-Lauri J (2002) Immunological weapons against acute myeloid leukaemia. Immunology 107:20–27PubMedCrossRef

19.

Gannage M, Abel M, Michallet AS, Delluc S, Lambert M, Giraudier S, Kratzer R, Niedermann G, Saveanu L, Guilhot F, Camoin L, Varet B, Buzyn A, Caillat-Zucman S (2005) Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol 174:8210–8218PubMed

20.

Greiner J, Li L, Ringhoffer M, Barth TF, Giannopoulos K, Guillaume P, Ritter G, Wiesneth M, Dohner H, Schmitt M (2005) Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood 106:938–945PubMedCrossRef

21.

Greiner J, Ringhoffer M, Simikopinko O, Szmaragowska A, Huebsch S, Maurer U, Bergmann L, Schmitt M (2000) Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp Hematol 28:1413–1422PubMedCrossRef

22.

Greiner J, Ringhoffer M, Taniguchi M, Hauser T, Schmitt A, Dohner H, Schmitt M (2003) Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer 106:224–231PubMedCrossRef

23.

Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H, Dohner H, Schmitt M (2004) mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 108:704–711PubMedCrossRef

24.

Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, Dohner K, Schlenk RF, Pollack JR, Dohner H, Bullinger L (2006) Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood. DOI 10.1182/blood-2006-01-023127

25.

Guinn BA, Bland EA, Lodi U, Liggins AP, Tobal K, Petters S, Wells JW, Banham AH, Mufti GJ (2005) Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 335:1293–1304PubMedCrossRef

26.

Guinn BA, Gilkes AF, Mufti GJ, Burnett AK, Mills KI (2006) The tumour antigens RAGE-1 and MGEA6 are expressed more frequently in the less lineage restricted subgroups of presentation acute myeloid leukaemia. Br J Haematol 134:238–239PubMedCrossRef

27.

Guinn BA, Gilkes AF, Woodward E, Westwood NB, Mufti GJ, Linch D, Burnett AK, Mills KI (2005) Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 333:703–713PubMedCrossRef

28.

Hinds DA, Stuve LL, Nilsen GB, Halperin E, Eskin E, Ballinger DG, Frazer KA, Cox DR (2005) Whole-genome patterns of common DNA variation in three human populations. Science 307:1072–1079PubMedCrossRef

29.

Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84:3071–3079PubMed

30.

The International HapMap Project (2003) Nature 426:789–796

31.

Jager D, Taverna C, Zippelius A, Knuth A (2004) Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. Cancer Immunol Immunother 53:144–147PubMedCrossRef

32.

Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jager D, Arand M, Ritter G, Cerundolo V, Dupont B, Chen YT, Old LJ, Knuth A (2000) Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 97:4760–4765PubMedCrossRef

33.

John AM, Thomas NS, Mufti GJ, Padua RA (2004) Targeted therapies in myeloid leukemia. Semin Cancer Biol 14:41–62PubMedCrossRef

34.

Kaufmann SH, Steensma DP (2005) On the TRAIL of a new therapy for leukemia. Leukemia 19:2195–2202PubMedCrossRef

35.

Knights AJ, Weinzierl AO, Flad T, Guinn BA, Mueller L, Mufti GJ, Stevanovic S, Pawelec G (2006) A novel MHC-associated proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemias. Leukemia 20:1067–1072PubMedCrossRef

36.

Kolb HJ, Rank A, Chen X, Woiciechowsky A, Roskrow M, Schmid C, Tischer J, Ledderose G (2004) In-vivo generation of leukaemia-derived dendritic cells. Best Pract Res Clin Haematol 17:439–451PubMedCrossRef

37.

Koya RC, Kasahara N, Pullarkat V, Levine AM, Stripecke R (2002) Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune responses. Leukemia 16:1645–1654PubMedCrossRef

38.

Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172–187PubMedCrossRef

39.

Kufner S, Fleischer RP, Kroell T, Schmid C, Zitzelsberger H, Salih H, de Valle F, Treder W, Schmetzer HM (2005) Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. Cancer Immunol Immunother 54:953–970PubMedCrossRef

40.

Li L, Reinhardt P, Schmitt A, Barth TF, Greiner J, Ringhoffer M, Dohner H, Wiesneth M, Schmitt M (2005) Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol Immunother 54:685–693PubMedCrossRef

41.

Li Y, Li H, Wang MN, Lu D, Bassi R, Wu Y, Zhang H, Balderes P, Ludwig DL, Pytowski B, Kussie P, Piloto O, Small D, Bohlen P, Witte L, Zhu Z, Hicklin DJ (2004) Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood 104:1137–1144PubMedCrossRef

42.

Lim SH, Austin S, Owen-Jones E, Robinson L (1999) Expression of testicular genes in haematological malignancies. Br J Cancer 81:1162–1164PubMedCrossRef

43.

Lowenberg B, Downing JR, Burnett A (1999) Acute myeloid leukemia. N Engl J Med 341:1051–1062PubMedCrossRef

44.

Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5:845–856PubMedCrossRef

45.

Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U (2004) Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18:165–166PubMedCrossRef

46.

Marijt WA, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, van der Hoorn MA, van Luxemburg-Heys SA, Hoogeboom M, Mutis T, Drijfhout JW, van Rood JJ, Willemze R, Falkenburg JH (2003) Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 100:2742–2747PubMedCrossRef

47.

Mathews V, DiPersio JF (2004) Stem cell transplantation in acute myelogenous leukemia in first remission: what are the options? Curr Hematol Rep 3:235–241PubMed

48.

Matsushita M, Ikeda H, Kizaki M, Okamoto S, Ogasawara M, Ikeda Y, Kawakami Y (2001) Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol 112:916–926PubMedCrossRef

49.

Matsushita M, Yamazaki R, Ikeda H, Kawakami Y (2003) Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies. Leuk Lymphoma 44:439–444PubMedCrossRef

50.

Meletis J, Viniou N, Terpos E (2006) Novel agents for the management of myelodysplastic syndromes. Med Sci Monit 12:RA194–RA206PubMed

51.

Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126–129PubMedCrossRef

52.

Morris E, Hart D, Gao L, Tsallios A, Xue SA, Stauss H (2006) Generation of tumor-specific T-cell therapies. Blood Rev 20:61–69PubMedCrossRef

53.

Mulford DA, Jurcic JG (2004) Antibody-based treatment of acute myeloid leukaemia. Expert Opin Biol Ther 4:95–105PubMedCrossRef

54.

Ohno R, Nakamura Y (2003) Prediction of response to imatinib by cDNA microarray analysis. Semin Hematol 40:42–49PubMed

55.

Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, Hosen N, Yoshihara S, Wu F, Fujiki F, Murakami M, Masuda T, Nishida S, Shirakata T, Nakatsuka S, Sasaki A, Udaka K, Dohy H, Aozasa K, Noguchi S, Kawase I, Sugiyama H (2004) Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101:13885–13890PubMedCrossRef

56.

Ota J, Yamashita Y, Okawa K, Kisanuki H, Fujiwara S, Ishikawa M, Lim Choi Y, Ueno S, Ohki R, Koinuma K, Wada T, Compton D, Kadoya T, Mano H (2003) Proteomic analysis of hematopoietic stem cell-like fractions in leukemic disorders. Oncogene 22:5720–5728PubMedCrossRef

57.

Padua RA, Larghero J, Robin M, le Pogam C, Schlageter MH, Muszlak S, Fric J, West R, Rousselot P, Phan TH, Mudde L, Teisserenc H, Carpentier AF, Kogan S, Degos L, Pla M, Bishop JM, Stevenson F, Charron D, Chomienne C (2003) PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med 9:1413–1417PubMedCrossRef

58.

Palmowski MJ, Choi EM, Hermans IF, Gilbert SC, Chen JL, Gileadi U, Salio M, Van Pel A, Man S, Bonin E, Liljestrom P, Dunbar PR, Cerundolo V (2002) Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 168:4391–4398PubMed

59.

Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA (2000) Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95:1781–1787PubMed

60.

Pinilla-Ibarz J, May RJ, Korontsvit T, Gomez M, Kappel B, Zakhaleva V, Zhang RH, Scheinberg DA (2006) Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia 20:2025–2033PubMedCrossRef

61.

Porter DL, Antin JH (2006) Donor leukocyte infusions in myeloid malignancies: new strategies. Best Pract Res Clin Haematol 19:737–755PubMedCrossRef

62.

Qazilbash MH, Wieder E, Rios R, Sijie L, Kant S, Giralt S, Estey EH, Thall P, de Lima M, Couriel D, et al (2004) Vaccination wth the PR1 leukaemia-associated antigen can induce complete remission in patients with myeloid leukaemia. Blood 104:259 (abstract)

63.

Raghavan M, Lillington DM, Skoulakis S, Debernardi S, Chaplin T, Foot NJ, Lister TA, Young BD (2005) Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res 65:375–378PubMed

64.

Reichardt VL, Brossart P (2005). Current status of vaccination therapy for leukemias. Curr Hematol Rep 4:73–76PubMed

65.

Robin M, Schlageter MH, Chomienne C, Padua RA (2005) Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans. Cancer Immunol Immunother 54:933–943PubMedCrossRef

66.

Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92:11810–11813PubMedCrossRef

67.

Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4:1PubMed

68.

Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, Nagorsen D, Keilholz U (2002) CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100:2132–2137PubMedCrossRef

69.

Schirrmann T, Pecher G (2005) Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor. Leuk Res 29:301–306PubMedCrossRef

70.

Scott BL, Deeg HJ (2005) Hemopoietic cell transplantation for the myelodysplastic syndromes. Arch Immunol Ther Exp 53:297–307

71.

Serafini P, Borrello I, Bronte V (2006) Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16:53–65PubMedCrossRef

72.

Siegel S, Steinmann J, Schmitz N, Stuhlmann R, Dreger P, Zeis M (2004) Identification of a survivin-derived peptide that induces HLA-A*0201-restricted antileukemia cytotoxic T lymphocytes. Leukemia 18:2046–2047PubMedCrossRef

73.

Siegel S, Wagner A, Kabelitz D, Marget M, Coggin J Jr, Barsoum A, Rohrer J, Schmitz N, Zeis M (2003) Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. Blood 102:4416–4423PubMedCrossRef

74.

Soen Y, Chen DS, Kraft DL, Davis MM, Brown PO (2003) Detection and characterization of cellular immune responses using peptide-MHC microarrays. PLoS Biol 1:E65PubMedCrossRef

75.

Tagliafico E, Tenedini E, Manfredini R, Grande A, Ferrari F, Roncaglia E, Bicciato S, Zini R, Salati S, Bianchi E, Gemelli C, Montanari M, Vignudelli T, Zanocco-Marani T, Parenti S, Paolucci P, Martinelli G, Piccaluga PP, Baccarani M, Specchia G, Torelli U, Ferrari S (2006) Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia. Leukemia 20:1751–1758PubMedCrossRef

76.

Tsuji T, Yasukawa M, Matsuzaki J, Ohkuri T, Chamoto K, Wakita D, Azuma T, Niiya H, Miyoshi H, Kuzushima K, Oka Y, Sugiyama H, Ikeda H, Nishimura T (2005) Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood 106:470–476PubMedCrossRef

77.

Van Driessche A, Gao L, Stauss HJ, Ponsaerts P, Van Bockstaele DR, Berneman ZN, Van Tendeloo VF (2005) Antigen-specific cellular immunotherapy of leukemia. Leukemia 19:1863–1871PubMedCrossRef

78.

Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292–2302PubMedCrossRef

79.

Villuendas R, Steegmann JL, Pollan M, Tracey L, Granda A, Fernandez-Ruiz E, Casado LF, Martinez J, Martinez P, Lombardia L, Villalon L, Odriozola J, Piris MA (2006) Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia 20:1047–1054PubMedCrossRef

80.

Walz C, Sattler M (2006) Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 57:145–164PubMed

81.

Wang Z, Zhang Y, Liu H, Salati E, Chiriva-Internati M, Lim SH (2003) Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. Blood 101:955–960PubMedCrossRef

82.

Wang Z, Zhang Y, Mandal A, Zhang J, Giles FJ, Herr JC, Lim SH (2004) The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies. Clin Cancer Res 10:6544–6550PubMedCrossRef

83.

Whiteside TL, Gooding W (2003) Immune monitoring of human gene therapy trials: potential application to leukemia and lymphoma. Blood Cells Mol Dis 31:63–71PubMedCrossRef

84.

Xue SA, Gao L, Hart D, Gillmore R, Qasim W, Thrasher A, Apperley J, Engels B, Uckert W, Morris E, Stauss H (2005) Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 106:3062–3067PubMedCrossRef

Titel: Immunotherapy of myeloid leukaemia
verfasst von: Barbara-Ann Guinn
Azim Mohamedali
N. Shaun B. Thomas
Ken I. Mills
Publikationsdatum: 01.07.2007
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 7/2007
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-006-0267-y

Springer Medizin

Immunotherapy of myeloid leukaemia

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2007

Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma

Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice

CD8+ T lymphocytes isolated from renal cancer patients recognize tumour cells through an HLA- and TCR/CD3-independent pathway

Oral premalignant lesions induce immune reactivity to both premalignant oral lesions and head and neck squamous cell carcinoma

CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab

Immune reconstitution prevents metastatic recurrence of murine osteosarcoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie